Adaptimmune
adaptimmune.comLocations
United States · United Kingdom · Oxton, York YO23 7AT, UK
industry
Health · Biotechnology · DeepTech
Size
201-1000 employees
Stage
IPO
founded in
2008
Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroys cancerous or infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was incorporated in 2007 and is based in Abingdon, United Kingdom.
Something looks off?Open jobs at Adaptimmune